Acute myeloid leukemia: when to transplant in first complete remission [0.03%]
急性髓系白血病首次完全缓解期何时进行移植治疗？
Brian T Hill,Edward A Copelan
Brian T Hill
Allogeneic hematopoietic stem cell transplantation (HSCT) is commonly used to treat acute myeloid leukemia (AML) because it is potentially curative when other therapies have a low likelihood of success. Although most patients with newly dia...
Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia [0.03%]
护理级别：定义老年急性髓系白血病患者的最佳支持治疗
Ellen K Ritchie,Gail J Roboz
Ellen K Ritchie
This article reviews published data on best supportive care (BSC) in older patients with acute myeloid leukemia (AML) and proposes improvements in defining this critical aspect of treatment. A clinical challenge is to prospectively identify...
Molecular monitoring of BCR-ABL transcripts in patients with chronic myelogenous leukemia: is high sensitivity of clinical value? [0.03%]
BCR-ABL基因转录本分子监测对慢性粒细胞白血病患者的临床意义与检测高敏感性有关吗？
Maxim Norkin,Charles A Schiffer
Maxim Norkin
Monitoring of disease response during treatment with tyrosine kinase inhibitors of patients with chronic myelogenous leukemia dramatically changed after the introduction of real-time PCR, which allows quantification of BCR-ABL transcript le...
G Vignir Helgason,Graham A R Young,Tessa L Holyoake
G Vignir Helgason
Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in w...
Meetu Agrawal,Ravin J Garg,Jorge Cortes et al.
Meetu Agrawal et al.
The treatment of chronic myeloid leukemia (CML) drastically changed with the introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), in 1998. By directly targeting this leukemogenic protein kinase, imatinib affords pa...
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma [0.03%]
单克隆免疫球蛋白血症及不分泌型多发性骨髓瘤
Robert A Kyle,S Vincent Rajkumar
Robert A Kyle
Monoclonal gammopathy of undetermined significance (MGUS) is characterized by the presence of a serum monoclonal (M) protein level less than 3 g/dL, less than 10% clonal plasma cells in the bone marrow, and the absence of hypercalcemia, ren...
Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis [0.03%]
减低强度预处理方案 Combined 单倍型相合造血干细胞移植治疗骨髓纤维化
Haefaa Alchalby,Nicolaus Kröger
Haefaa Alchalby
Hematopoietic stem cell transplantation offers a curative therapy for patients with myelofibrosis. Because of toxicity, allografting following myeloablative regimens is mainly applicable to young patients. With the introduction of dose-redu...
Challenges in the frontline treatment of patients with chronic lymphocytic leukemia [0.03%]
慢性淋巴细胞白血病一线治疗的挑战
Nicole Lamanna
Nicole Lamanna
Therapy for chronic lymphocytic leukemia has improved dramatically over the past 20 years. Traditional therapy with oral chlorambucil led to complete responses in less than 5% of treated patients, in marked contrast to modern regimens, whic...
Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment? [0.03%]
慢性淋巴细胞白血病的微小残留病灶清除治疗：是否应当成为治疗目标？
Abraham M Varghese,Andy C Rawstron,Peter Hillmen
Abraham M Varghese
Even though chronic lymphocytic leukemia (CLL) is the most prevalent leukemia of the Western world, the development of treatment approaches for CLL has lagged behind the development of approaches to various other hematologic malignancies fo...
Thomas S Lin
Thomas S Lin
Despite advances in treatment, chronic lymphocytic leukemia (CLL) remains incurable with standard therapies. Novel therapeutic agents are needed, particularly for patients with high-risk cytogenetic abnormalities such as del(17p13). The pas...